The Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.
Cigna Corp. raised the health insurer’s annual adjusted profit forecast on May 6, following a decline in COVID-related costs and no sign of pent-up demand for medical procedures that were delayed due to the pandemic.
The Digital Medicine Society (DiMe), in partnership with Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer and Savvy Co-op, announced the public launch of the 3Ps of Digital Endpoint Value (3Ps), a toolkit of resources created to facilitate the inclusion of digital endpoints as evidence for payers in reimbursement decisions for new drugs.
More than 14.5 million Americans signed up for Obamacare health insurance for 2022, a 21 percent jump over 2021 and the highest since the Affordable Care Act was signed 12 years ago, the U.S. government said on March 23.
Anthem Inc. intends to change its name to Elevance Health Inc., as the company looks to shift its focus beyond the health insurance business.
Biogen shares fell on January 12 after the Centers for Medicare and Medicaid Services (CMS) issued its draft national coverage decision for the company’s controversial Alzheimer’s drug Aduhelm.
The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.
Insurance companies will be required to cover eight over-the-counter at-home coronavirus tests per person each month starting January 15, the Biden administration said, expanding access to highly sought-after kits as Americans grapple with a surge in coronavirus cases.
Union leaders representing 50,000 nurses and other U.S. medical staff reached a tentative agreement with Kaiser Permanente on November 13, averting a strike that could have disrupted patient care at hospitals.
Biogen Inc. is pinning hopes on a decision on U.S. government coverage of the company’s Alzheimer’s disease drug during 2022 to help drive up Aduhelm’s usage, after a big miss on third-quarter 2021 sales of the much-awaited treatment.
